Literature DB >> 6434916

Neutron leakage measurements from a medical linear accelerator.

J R Palta, K R Hogstrom, C Tannanonta.   

Abstract

The McCall method has been used to measure neutron leakage from the Mevatron 77, 18- and 15-MV photon beams. Gold foil activation has been used employing a beta counting technique for the 18-MV beam and a gamma counting technique for both the 18- and 15-MV beam. The two counting techniques were used to evaluate their relative merit. The measurements were made at various locations in the patient-treatment plane for different field sizes. The results show that the thermal-neutron dose equivalent contributes only about 1%-2% of the total neutron dose equivalent. At 100 cm, the neutron dose equivalent for the 18-MV beam is approximately six times that of the 15-MV beam, slightly exceeding the 0.1% of the useful beam criteria used by some of the regulatory agencies. In light of the uncertainty in fluence to dose equivalent conversion factors, the increased dose equivalent above 0.1% is insignificant.

Entities:  

Mesh:

Year:  1984        PMID: 6434916     DOI: 10.1118/1.595543

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  3 in total

Review 1.  A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction.

Authors:  X George Xu; Bryan Bednarz; Harald Paganetti
Journal:  Phys Med Biol       Date:  2008-06-09       Impact factor: 3.609

2.  Neutron source strength measurements for Varian, Siemens, Elekta, and General Electric linear accelerators.

Authors:  David S Followill; Marilyn S Stovall; Stephen F Kry; Geoffrey S Ibbott
Journal:  J Appl Clin Med Phys       Date:  2003       Impact factor: 2.102

3.  Out-of-field doses and neutron dose equivalents for electron beams from modern Varian and Elekta linear accelerators.

Authors:  Carlos E Cardenas; Paige L Nitsch; Rajat J Kudchadker; Rebecca M Howell; Stephen F Kry
Journal:  J Appl Clin Med Phys       Date:  2016-07-08       Impact factor: 2.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.